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Background: Schizophrenia is a complex, heterogeneous disorder, with highly variable treatment outcomes, and
relatively little is known about what is important to patients. The aim of the study was to understand treatment
outcomes informal carers perceive to be important to people with schizophrenia.
Method: Qualitative interview study with 34 individuals and 8 couples who care for a person with schizophrenia/
schizoaffective disorder. Interviews were transcribed verbatim and analysed by a thematic framework based approach.
Results: Carers described well-recognised outcomes of importance, alongside more novel outcomes relating to: Safety
(of the patient/others); insight (e.g. into non-reality of psychotic phenomena); respite from fear, distress or pain; socially
acceptable behaviour; getting out of the house; attainment of life milestones; changes in personality and/or
temperament; reduction of vulnerability to stress; and several aspects of physical health.
Conclusions: These findings have the potential to inform the development of patient- or carer- focused outcome
measures that take into account the full range of domains that carers feel are important for patients.
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Improving treatment outcomes and quality of life for
people with long-term mental health conditions are key
aims of health care policy [1, 2]. Schizophrenia is a particu-
larly important target, being associated with poor quality of
life [3] and individual and societal impacts [4–6], and re-
quiring long-term treatment [7]. Antipsychotic medications
can ameliorate some symptoms and improve quality of life
[3, 8, 9], but individual responses vary [10, 11], and many
discontinue medication due to poor efficacy or debilitating
side effects [12, 13]. Treatment outcomes are often assessed
by clinician ratings, and/or symptom scales [14], but
patients and carers may prioritise different outcomes to
clinicians [15–17], and controlling symptoms is not the
only outcome of importance [14]. The recovery literature
draws attention to the importance of recognising a broad
array of outcome domains in schizophrenia treatment,* Correspondence: Michele.peters@dph.ox.ac.uk
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functioning, alongside subjective wellbeing, optimism and
empowerment (e.g. [18, 19]). Patients and relatives, in
particular, refer to subjective wellbeing when defining
‘remission’, in contrast to traditional clinical definitions
focused around reduced symptom scores [17]. People with
schizophrenia value outcomes such as achieving life mile-
stones, feeling safe, improved physical activity, employment,
a positive sense of self and psychosocial outcomes [20].
Understanding the full range of treatment outcomes
important to people with schizophrenia and their carers is
key for ensuring that clinical practice, research and assess-
ment are aligned with patient and carer priorities [4, 21].
While people with schizophrenia can give valid and reli-
able accounts of outcomes [22–24], symptoms can make it
difficult to participate in research [25], and carers represent
a valuable additional resource [15, 21, 26]. Furthermore,
carers have the potential to influence treatment decisions
[26], and experience, indirectly, the impact of outcomes.
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existing literature on treatment outcomes of importance to
patients and carers, and a consensus conference with pro-
fessionals, carers and patients, and aimed to identify
whether carers report any outcome domains that have not
been emphasised in the current literature.
Method
Design of the study
A qualitative study using in-depth semi-structured inter-
views was conducted with self-identified ‘carers’ of a family
member with a diagnosis of schizophrenia made at least
2 years previously. Ethical approval was obtained from
NHS East of Scotland Research Ethics Service (EoSRES)
REC 1 by proportionate review (Application Number 13/
ES/0143). All participants gave written informed consent.
Participants and recruitment
A total of 34 individuals and 8 couples were interviewed
(i.e. 50 people in 42 interviews). While qualitative method-
ology papers tend to avoid prescribing hard guidelines for
sample sizes for qualitative studies, 25–30 participants
have been deemed an acceptable minimum by Dworkin
[27] and this number is usually sufficient for reaching data
saturation. An email circulated by charity ‘Rethink Mental
Illness’ was responded to by 102 people who were
screened via telephone to confirm that they were the carer
of someone with a ≥ 2-year diagnosis of schizophrenia or
schizoaffective disorder. Within this self-selecting con-
venience sample, participants were then recruited purpos-
ively to generate a relatively heterogeneous final sample,
consisting of 38 females and 12 males, aged from 20s–80s
(48% in their 60s, 26% in their 50s, and the remainder in
their 20s, 40s, 70s or 80s), and coming from urban (e.g.
Greater London) and rural (e.g. Wiltshire) locations.
Thirty-seven were the mother of a person with schizo-
phrenia, 10 were the father or stepfather, one the husband,
one the wife, and one the sibling. Duration of illness of the
patients discussed ranged from 2 to 20+ years, with a
modal duration of 11–15 years (42%). The majority
(n = 44) cared for someone with schizophrenia, and six
cared for someone with schizoaffective disorder.
Interviews
Most participants chose to be interviewed at home, but ap-
proximately 20% chose to come to the University. At the
beginning of the interviews, carers re-confirmed that the
patient had received a formal diagnosis of schizophrenia or
schizoaffective disorder from a GP or psychiatrist, at least
two years prior to the interview. Carers were then asked
what they felt were important outcomes of treatment for
the patient who they cared for: at present; at a time when
the patient was particularly ill or unwell; at a time when
they were more stable; and at a time when they were doingparticularly well. Prompts were designed to encourage
participants to discuss both directly-experienced outcomes,
and important/desired but unattained outcomes. In
addition, a series of prompts relating to key outcomes were
compiled based on the conceptual review of the literature
and feedback from a consensus conference, but were not in
fact utilised in any of the interviews, as participants
spontaneously discussed a broad array of outcomes of
importance in response to the preliminary, general
questions. After the initial 6 interviews, when it became
apparent that participants identified multiple outcomes in
response to the primary questions, without need for
prompts, the researchers agreed that all future interviews in
the study would proceed without prompts. Carers were
encouraged to expand upon ideas that they themselves
raised in relation to outcomes, rather than directed towards
any specific topic. It was felt that this strengthened the data,
as it reduced the potential for investigator bias. The topic
guide, which was reviewed for tone and content prior to
use by two carers and one person with schizophrenia, can
be found in online Additional file 1. Interview duration
ranged from 40 to 125 min (average, approx. 60 min).
Analysis
Interviews were transcribed verbatim by a professional
transcriber, and anonymised. Transcripts were analysed in
NVivo 8 by JL, using a thematic, framework based
approach [28]. This involved the creation of a preliminary
framework based on a literature review and consensus con-
ference. Transcripts were then analysed, with themes being
coded into appropriate categories within that framework,
wherever appropriate categories existed. Where themes did
not fit well into an existing category, novel categories were
created. Interviews were continued until no further novel
categories emerged, by which point all categories had been
spontaneously mentioned by several participants, and
saturation was deemed to have been reached. Once all in-
terviews had been coded, the categories were reviewed by
the research team, to ensure that they were representative
of all the statements coded within them. Where categories
were ambiguous, e.g. contained material that could poten-
tially be better conceptualised within different domains, or
could be better represented by different titles, they were re-
vised, and the material coded within them was re-coded in
order to ensure that it was coded within the most appropri-
ate category. A final framework that encompassed the ori-
ginal and the novel categories was then agreed amongst the
researchers. All of the interviews were then re-coded, using
the final framework. In this second iteration, the majority
of the material was coded into the same categories as dur-
ing the initial coding. However, this process was important
to ensure that any statements that had originally been
coded into categories within the preliminary framework,
but in retrospect better-reflected a novel category that had
Table 1 Summary of treatment outcomes of importance
(as identified by carers)
Symptom-related outcomes
➢ Positive symptoms
[50–53]d
➢ Cognitive symptoms
[50–53]d
➢ Affective symptoms
[50–53]d
➢ Safetyd
➢ Negative symptoms
[51–54]d
➢ Stability (relapse/
hospitalisation)
[51, 55–57]d
➢ Side-effects
[21, 29, 58–60]d
➢ Fear/distress/paind
➢ Insightd
Quality of life
➢ Motivation and energy
[61, 62]d
➢ Physical functioning
[61, 62]a
➢ Life satisfaction
[61, 62]b
➢ Emotional regulation/
Self-control [61, 62]c
➢ Stigma [63]c
➢ Leading a normal life
[50]d/social
acceptability [61, 62]d
Functional outcomes
➢ Independence [21, 53, 64]d
➢ Role functioning/productivityd
(family/home/education/
work/petsb) [21, 29, 53, 64]
➢ Life milestonesc
➢ ADLs [15, 48]/Self-care
[21, 53, 64]d
➢ Social / relationships
[21, 29, 53, 64]d
➢ Leisure pursuits [53, 64]
[34, 48]d/
getting outd
Personal recovery
➢ Developing positive identity
[65, 66]d
➢ Finding meaning in life
[65, 66]c
➢ Accepting help/support
from others [67]d
➢ Learning about
(& managing/monitoring)
illness/treatment/services
[68]d
➢ Overcoming ‘stuckness’
[65, 66]d
➢ Vulnerability/sensitivityd
➢ Aiming for goals/
‘new potentials’ [66, 67]c
➢ Taking responsibility/
decision-making [65]d
➢ Developing hope/
optimism [65, 67–69]c
➢ Participating in
life-enriching
activities [66]c
➢ Becoming more
empowered [66–68]c
➢ Personality/
temperamentd
Physical health and lifestyle
➢ Exercise/physical
activityc
➢ Diet/weightd
➢ Alcohol/drugs/
smokingc
➢ Routinec
➢ Sleepc
Satisfaction with treatment
➢ Satisfaction with
medication [70]c
➢ Satisfaction with
therapeutic
relationship [71]d
Key: Number of interviews in which one or more of the carers referred to the
outcome: afew (n = 1–4), bsome (n = 5–10), cmany (n = 11–21), dmost (n ≥ 22).
References cited indicate sources where the same treatment outcomes of
importance have previously been identified. ADLs = activities of daily living
Outcomes presented in italics have not been described in previous studies but
stem directly from the findings of this study
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ately. RF and MP independently cross-checked the final
categorisation by coding a random selection of 6
transcripts, and no disagreements emerged. Categorized
data were summarized and synthesized, and the resultant
categories (and associations between them) were inter-
preted in relation to the categories already identified within
the literature and consensus conference. After the final
coding, the number of interviews in which each category
occurred was calculated.
Results
Overview
Outcomes of importance in schizophrenia reported by the
carers included symptom related outcomes, quality of life,
functional outcomes, personal recovery, physical health
and lifestyle, and satisfaction with treatment. Table 1 lists
these outcomes, and their sub-categories, and the propor-
tion of interviews in which they occurred (using the con-
ventions: ‘few’ for 2–10% (n = 1–4), ‘some’ for 12–24%
(n = 5–10), ‘many’ for 25–50% (n = 11–21), and ‘most’ for
>50% (n = 22–42)). It was not necessary for a participant
to overtly state that an outcome had been experienced by
the person they care for, in order to code their statement
as an endorsement of that domain. While ‘endorsement’
of an outcome domain did, in some cases, take this form,
any statement that either explicitly or implicitly indicated
that a domain was relevant or important to that carer, was
also coded within that domain. For example, where a carer
identified that the person they cared for experienced
ongoing difficulties with engaging in physical activity, or
that they wished the person they cared for could have the
energy to engage in physical activity, this was interpreted
as the carer indicating that being able to engage in
physical activity was an important outcome, and hence it
was coded within the ‘physical activity’ category.
The categories in Table 1 were first identified through a
literature review and consensus conference and subse-
quently adapted to include the newly identified and/or ex-
panded categories from the interview data reported here.
Standard font indicates categories which were pre-
identified from the literature review (and replicated in the
current study), and italic font indicates novel/ modified
categories which emerged from the current study (which
are illustrated by quotations in Tables 3 and 4, and
discussed below). All categories in Table 1 were identified
as relevant by at least some of the carers interviewed, and
the majority were mentioned in >50% of the interviews.
Symptom-related outcomes (Table 2)
Safety was mentioned in most interviews, and encompassed
safety from dangerous behaviours prompted by psychosis
(such as absconding/ putting oneself or others into risky sit-
uations); from health risks linked to negative symptoms(e.g. not eating, living in squalor); and from potential for
deliberate self-harm related to affective symptoms.
‘It's great for it to be diagnosed, to be put on your
medication and you're safe’ [C41]
Table 2 Quotations to illustrate symptom-related and quality of
life related outcomes
Symptom-related outcomes
Safety (of self/others)
• ‘Her behaviour became so risky in a way, and it was so
difficult with her at home.’ [C50]
• ‘When he’s psychotic… he’s a danger to himself and he
could be a danger to other people.’ [C26&27]
• ‘You’re at risk the whole time and a bit more vulnerable.’ [C07]
Fear/distress/pain
• ‘It’s an effort and it’s almost a pain, it’s almost like a
physical pain for him to stay normal.’ [C09]
• ‘I know that he’s distressed by the psychosis. You know
he’s seeing things that are really awful…
• ‘If I look back, when medication was introduced [um] he
probably was less distressed.’ [C24]
• ‘I think the worst thing was that… why should he have
so much suffering?’ [C13]
Insight
• ‘He’s doing very well at the moment although he’s in
hospital. But the reason is that he has total insight…
He knows what’s real… that has been the biggest
progress.’ [C07]
• ‘To recognise that it’s his illness that’s giving him his
thoughts, that’s giving him his voices.’ [C09]
• ‘She knows the difference between a paranoid thought
and quote, a normal thought. So she knows when these
thoughts are coming… and can begin to tackle them.’ [C22]
• ‘He’s come to the realisation that he does need an
anti-psychotic.’ [C11]
Quality of life
Social acceptability
• ‘[Medication allows her] to behave appropriately and you
know [um]… in family situations.’ [C04&05]
• ‘Medication’s allowing him to be in the community and it’s
allowing the community to be safe.’ [C12]
• ‘Unusual behaviour. Is there anything that can be done
about that?’ [C20]
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and emotional (or even physical) pain was raised in most in-
terviews, often closely related to positive symptoms, but at
the level of their physical and emotional consequences.
‘He was absolutely intimidated by his environment…
he felt frightened and threatened’ [C25]
Insight was also mentioned in most interviews, encom-
passing both recognition that current/prior psychotic phe-
nomena are not real, and understanding that one has a
long-term illness. It was described as a gatekeeper to many
other treatment benefits, partly through its impact upon
treatment adherence, and was important in helping people
deal with residual psychotic phenomena.‘He can rationalise…although he hears the voices he
has a sense of reality.’ [C40]
Side-effects are not described in detail here as they are
well reported within existing literature (e.g. [29]), but
they were identified as important in the majority of
interviews, and in addition to commonly-reported side
effects (e.g. weight gain and fatigue), a few participants
mentioned negative impact of medication on imagin-
ation and/or creativity, and concerns over toxicity of
medication during pregnancy and breastfeeding.
Quality of life (Table 2)
The concept of ‘social acceptability’ was raised in most
interviews, i.e. behaving in a socially appropriate way
and avoiding bizarre/unconventional behaviour. Many
discussed the importance of treatment in helping pa-
tients avoid illegal behaviour (sometimes precipitated by
symptoms).
‘[When] he's not taking his medication, he occasionally
offends people in the street’ [C25]
Functional outcomes (Table 3)
The domain of ‘life milestones’ was added to encompass
many carers’ reports of the importance of reaching key life/
developmental milestones, such as attaining qualifications,
learning to drive, moving out of the caregiver’s home, or
having a family.
‘I think he missed out all his twenties and thirties so
maybe catching up in some ways.’ [C03]
Simply ‘getting out’ of the house was mentioned in most
interviews, and was consequently added as a sub-category
of ‘leisure pursuits’. This encompassed the importance of
being well enough to leave the house, which was some-
thing many patients needed to achieve before the more
ambitious step of engaging in structured leisure activities
or even activities of daily living.
‘The worst time that we've had was… when he was so
unwell he didn’t go out the house for a year’ [C24]
A novel sub-category of ‘pets’ was added within the
‘role functioning and productivity’ category, because the
importance of being able to care for a pet was raised in
some interviews.
Personal recovery (Table 3)
The importance of ‘personality/temperament’ was raised
in most interviews, and was often particularly valued by
carers themselves. This encompassed emergence of as-
pects of the patient’s character, such as sense of humour,
Table 4 Quotations to illustrate physical health and lifestyle
related outcomes
Physical Health and Lifestyle
Exercise/physical activity and diet/weight
• ‘He was having plans. He said, “I need to go swimming, I want
to get fit and I want to go swimming.” He wouldn’t go into the
swimming pool because there are other people there.’ [C51]
• ‘The only pleasure he had in life in the end, after being
institutionalised and losing all the interests that he’d got… was
eating you know.. I’ll send out for a pizza, that’ll be nice and I’ll
watch a DVD and that’s about as…and a couple cans of lager and
that’s about as normal as things got for him really…’ [C46]
• ‘He can actually go down now and buy fresh fruit and vegetables…
He couldn’t make decisions; [um] he didn’t know what food to
eat… He didn’t have a fridge.’ [C25]
• ‘She got anorexic, she wasn’t eating at all; she wasn’t drinking
because she thought the water was contaminated. Physically she
was going downhill because she wasn’t eating or drinking.’ [C14&15]
Alcohol/drugs/smoking
• ‘He was self-medicating with alcohol. For quite a long while…
he actually stopped drinking. And that helped a lot of things and it
helped with the medication and generally with his mood.’ [C40]
• ‘Once they’ve become established, or on a working medication,
they don’t need the cannabis. Maybe it’s they don’t need it, maybe
that they’ve become well enough in order to have insight to know
that it’s harmful to them.’ [C10]
• ‘She’s a confirmed smoker… It’s the least of our problems I think,
you know.’ [C04&05]
Routine
• I feel a lot better now he’s at college because he has to get up,
he has to go out, he’s got something to do. So that’s really good
because it’s horrible to watch somebody doing nothing all day.’
[C21]
• ‘The only reason that [1]‘s working now… is because of this
family… have made her do things and she’s living proof that if
you get into a routine you can do things.’ [C38]
• ‘He has some physical problems with sleeping. His sleeping is a
little erratic. He might not sleep very well at night but he catches up
during the day. So his life balance is different to probably you or I.
But he manages that in his way now.’ [C40]
• ‘They need a reason to get up, need a reason to get up in the
morning’ [C28]
Table 3 Quotations to illustrate functional and personal
recovery related outcomes
Functional outcomes
Life milestones
• ‘He said [um], “I’m grown up now Mum,” and he didn’t see
me for a long time… as though he’s struck out to be an adult…
but he wanted to start where he left off when he was a
teenager.’ [C03]
• ‘He wants to get married; he’d love to have children…
you know he wants to have the life that everybody else has
and he didn’t see himself not having that life and he’s like
forty now and it’s like, you know, where have those twenty
years gone when I should have been doing all this.’ [C32&33]
• ‘Bear in mind she’s still, almost her development stopped when
she was 17 as an adult.’ [C38]
Getting out
• ‘He’s been able to go out because before, he was frightened
to go out not only because of what was out there, but because
inside himself he couldn’t actually get out the door.’ [C06]
• ‘For three years she didn’t really do anything, she just, for three
years she was just at home… sleeping a lot and watching tele
and not going out and generally not living.’ [C19]
Pets
• ‘He’d said… “I can’t manage myself let alone a dog”… it’s only
recently that he said, “Oh yeah I think I’m up to having a dog,”
so that’s a really good step forward.’ [C14&15]
• ‘He loved the kitten but I thought he can look after the kitten…
but he wouldn’t, he wouldn’t look after it, he just loved it. It’s a
cat now and he still loves it but he still won’t look after it.’ [C51]
Personal Recovery
Personality/temperament
• ‘He’s much easier when he’s on medication, he’s much more
like himself and [um], oh god when he’s not on it I have to
watch every word I say.’ [C12]
• ‘I could see beneath his anxious anxiety and still his distress
and everything, that there he was, my son that I knew whereas
I’d lost sight of it completely before… I began to see the [1]
that I knew before he became ill. He got his sense of humour
back… I began to see his own personality coming back.’ [C09]
• ‘Becoming more friendly, becoming more co-operative…
more considerate, thoughtful.’ [C03]
Vulnerability/sensitivity
• ‘He’s very sensitive, very, very sensitive… he gets very stressed
doesn’t he.’ [C14&15]
• ‘Until the stress was sort of plonked upon him and then the
medication wasn’t quite enough.’ [C23]
• ‘It was times of stress and things…whether things went wrong
then we’d get the paranoia then... he can’t take any stress that’s
the thing.’ [C32&33]
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calmer temperament, more ‘like oneself ’.
‘He reverted to his old self. You could reason with him,
you could have a laugh with him’ [C46]The vast majority of carers also mentioned ‘vulnerabil-
ity/sensitivity’ to all kinds of stress, in most cases as a
residual difficulty that treatment failed to resolve, rather
than a positive, attained outcome.
‘Although he seems fairly even I don’t think it would
take a huge amount to kick him over the edge.’ [C06]Physical health and lifestyle (Table 4)
Exercise/physical activity and diet/weight were raised by
the majority of carers, who sometimes described how
treatment facilitated physical activity and healthy diet
(by improving symptoms that create barriers), but also
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tite/metabolism, and fatigue) could act as barriers.
‘On such a high dose… of a sedating medication.
Motivation is just not there’. [C46]
Many described the importance of outcomes related to
drugs/alcohol/smoking, such as decreased reliance upon
substances previously used to self-medicate positive or
affective symptoms, or compensate for lack of social/
functional activities.
‘She was drinking herself to sleep, I think, mostly
because she had recurrent nightmares, and day time
nightmares’ [C50]
Daily routine was mentioned in many interviews, in
relation to sleep and waking, eating and self-care, and
was described both as a factor that contributed to im-
proving other outcomes, and as an outcome in itself.
Discussion
Principle findings
All the schizophrenia treatment outcomes identified in the
literature review and consensus conference preceding the
study (i.e. symptom-related outcomes; functional outcomes;
personal recovery; quality of life; and satisfaction with treat-
ment) were confirmed in these qualitative interviews, along
with several novel sub-categories within existing domains
and a novel category of physical health and lifestyle, thus
giving a deeper understanding of outcomes in this condi-
tion. While a large proportion of the sample endorsed most
of the themes, it should be noted that frequency informa-
tion are indicative of the frequency of these domains within
our sample, and cannot be extrapolated from to estimate
the prevalence of these concerns in carers of persons with
schizophrenia.
While the importance of physical activity for persons
with schizophrenia is recognised within the literature [30],
and low levels of physical activity have been demonstrated
empirically to be associated with poorer outcomes in
schizophrenia [31], its importance as a treatment outcome
is not expressed in existing outcome measures. This high-
lights the need to consider physical activity as a potentially
relevant outcome domain in its own right. Designing
interventions for schizophrenia that include attention to
physical health and lifestyle, could help improve outcomes
for many patients.
Safety of the patient (and those around them), and reduc-
tion of their fear, distress or pain, were considered import-
ant by most carers, and it is easy to see why they would
value these outcomes, relating to resolution of negative
practical and emotional consequences of symptoms. While
the importance of these outcomes may be intuitive, theyare not explicitly represented in current outcome measures,
and this study is novel in highlighting their particular
salience. These outcomes could be described as ‘secondary’,
in the sense that they could be logically expected to follow
on from the more ‘primary’ outcome of amelioration of
(particularly, positive) symptoms. However, it could also be
argued that there are other means of reducing patients’ fear,
distress, or pain, aside from by symptom resolution, and
thus outcome measures could benefit from assessing the
extent to which treatments help to reduce a patient’s
experience of these negative states. This could help
professionals to gain a fuller understanding of how a given
treatment programme is impacting on the individual’s level
of fear and distress.
Most carers also valued insight which they often re-
ported to be associated with improved communication
with the person with schizophrenia, and a return of their
personality and/or of a more favourable, ‘normal’ tempera-
ment. This is consistent with findings that insight in
schizophrenia is associated with social cognition [32], and
lower scores on an aggression scale [33]. Carers also
described insight’s importance for enabling patients to
apply cognitive strategies to counter paranoid thoughts,
delusions or hallucinations, consistent with the finding
that insight can be predictive of prognosis [34]. Monitor-
ing level of insight may be beneficial in order to inform
decisions about when cognitive interventions may be more
effective. Exploring the value of educating carers in ways
to cope with poor insight in the person for whom they
care, could be another important target for future work.
Within functional outcomes, many carers talked of ‘get-
ting out’ (i.e. leaving the house), similar to the existing do-
main of engaging in leisure pursuits, but at a more
preliminary level. Caring for pets, similarly, could be con-
ceptualised as a specific form of role functioning/product-
ivity. Where residual difficulties are considerable and/or
recovery is particularly limited, less ‘ambitious’ functional
outcomes such as these may be particularly relevant. This
is consistent with the observation that traditional social
functioning measures may not be relevant to people with
severe disabilities related to schizophrenia [35], and with
carers’ comments about reduced potential and lowering of
expectations. From carers’ references to a range of key
developmental/life events such as moving out of the
family home, getting a job, learning to drive, and having a
romantic relationship, we identified ‘reaching life mile-
stones’ as an important and novel outcome. Because
schizophrenia onset is typically during adolescence or
early adulthood [36], before traditional milestones have
been reached, it is logical that the reaching of milestones
would for many be the goal, rather than the resumption of
familial, domestic, occupational or educational roles and
responsibilities. This highlights the fact that functional
outcome measures in schizophrenia may need to take
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ately capture small gains.
Within the realm of ‘personal recovery’ many carers
highlighted the importance of changes in personality and
temperament, and several described the return of the
person they used to know as the most important outcome;
understandably so, considering that these are good outward
indicators of wellness and ‘personal recovery’ and directly
impact upon the patient-carer relationship. Indeed, tem-
perament has been linked with functional outcomes and
psychological health [37]. Also relating to personal recov-
ery, many carers discussed patients’ vulnerability (to stress,
and in general) and sensitivity, consistent with empirical
findings of increased biological reactivity to stress in schizo-
phrenia [38]. These were typically described as residual
unresolved difficulties, and several carers reported that they
limited patients’ attainment of functional outcomes and
acted as precipitants of relapse, requiring careful monitor-
ing. This could indicate a potential benefit to be found in
involving carers, where appropriate, in helping patients to
monitor level of stress, and react quickly to try and reduce
its impact.
In the sub-category of ‘leading a normal life’, a number of
carers spoke of the importance of treatment for helping
patients to avoid socially unacceptable/antisocial/illegal
behaviours, (often precipitated by positive symptoms), in
order to reduce risk of arrest or sectioning, facilitate social
interactions and minimise stigma – consistent with findings
that socially unacceptable behaviour is strongly associated
with stigma in schizophrenia [39].
Consistent with other studies, many carers expressed de-
sire for greater monitoring of physical health [40]. Exercise/
physical activity, diet, and weight were all salient concerns;
again consistent with findings of elevated obesity [41] and
low activity [42] in schizophrenia/severe mental illness. A
wide range of contributing factors were cited by the carers,
including medication side effects, positive, negative and
affective symptoms, and eating replacing less attainable
leisure pursuits. Several also described patients who used
alcohol or drugs to self-medicate and/or compensate for a
lack of alternative leisure outlets; consistent with reported
motivations for substance use in schizophrenia [43]. Some
carers did describe physical health benefits of treatment,
e.g. where it reduced use of drugs or alcohol for self-
medication, or reduced symptoms enough to allow patients
to exercise or shop for healthy food. In relation to lifestyle
more generally, several carers emphasised the importance
of routine, as a desirable outcome and useful intervention
for facilitating the attainment of other outcomes (consistent
with a study where people with schizophrenia rated
organization of time as a useful coping strategy [44]). The
discovery that physical health is an important concern in
schizophrenia is not novel, but this study does support the
growing body of work emphasising the importance ofincorporating physical health interventions into schizophre-
nia treatment programmes (e.g. [45]).
Strengths and limitations
This study confirms the key treatment outcome categories
found in the current literature, and contributes evidence
of additional outcomes that carers feel are important for
patients but are not apparently captured in current think-
ing about, and measurement of, schizophrenia outcomes.
However, there are some possible biases in the sample.
The majority of carers interviewed were parents of a
person with schizophrenia, with a gender bias in the sam-
ple, such that around three quarters of participants were
female. However, this is in line with the gender balance
found in other convenience samples of carers of persons
with schizophrenia [46], and reflects the fact that mothers
are most frequently the primary carer in schizophrenia
[47]. It is possible that spouses, siblings, or children (or
those of a younger age in general) may have different
perceptions of what the important outcomes are. Most
participants were recruited via Rethink Mental Illness,
which may have meant they were particularly well-
informed about features of schizophrenia and issues
around treatment. Finally, the patients discussed were typ-
ically quite advanced in chronicity (in most cases >10 years
post-diagnosis). While carers were asked to discuss out-
comes that they felt were important at different phases of
illness, it is nevertheless possible that carers of patients
more immediately post-diagnosis would report different
outcomes. Future studies could benefit from exploring
outcomes with younger carers with different relationships
to the patient, from a range of backgrounds, and those
caring for people more early post-diagnosis.
The outcomes carers identified as being important for
patients may not be identical to the outcomes that patients
themselves would identify. However, there is generally good
agreement between the two [21], and as agents who
potentially influence patients’ treatment decisions [16], and
experience the consequences of the illness [48], carers’
views are important in their own right. Furthermore, we
were able to gain insight into outcomes that might not
otherwise have been represented, as most of the carers
interviewed reported that the patients they were speaking
about would have been unwilling/unable to participate (e.g.
‘he hates talking about it when he was really ill… he said,
“It makes me feel so ill again” [C41]).
Conclusions
The findings from this study contribute to our understanding
of the full range of treatment outcomes that carers feel are
important to people with schizophrenia, and could contribute
to ensuring research, treatment planning and assessment are
aligned with the needs and priorities of patients [4]. The
breadth of information gleaned from these interviews with
Lloyd et al. BMC Psychiatry  (2017) 17:266 Page 8 of 10family carers indicates what an important resource this popu-
lation represents. Furthermore, it is clear that informal carers
typically bear a high burden of care in schizophrenia [49].
Working with carers to gain insights and coordinate
interventions, where appropriate, could be a valuable way for
professionals to develop person-centred approaches in
schizophrenia. Outcomes of treatment should ideally be
assessed with measures that both complement existing
clinical scales and incorporate patient and carer priorities.
The domains and more specific experience emphasised here
should inform the further development of such patient- or
carer- focused outcome measures in order to ensure more
appropriate and complete evaluation of interventions.
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